# Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation

> **NCT03053180** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 60 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03053180
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-20
- **Primary completion:** 2017-12-18
- **Final completion:** 2017-12-18
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03053180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03053180, "Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03053180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*